Holen Sie sich die Stockscreener-App
3.05
5.57%
-0.18
Handel nachbörslich:
3.02
-0.03
-0.98%
Schlusskurs vom Vortag:
$3.23
Offen:
$3.24
24-Stunden-Volumen:
8,716
Relative Volume:
0.33
Marktkapitalisierung:
$16.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.5515
EPS:
-5.53
Netto-Cashflow:
$-12.27M
1W Leistung:
-4.54%
1M Leistung:
+1.33%
6M Leistung:
-25.06%
1J Leistung:
-22.19%
1-Tages-Spanne:
$3.02
$3.24
1-Wochen-Bereich:
$3.02
$3.39
52-Wochen-Spanne:
$2.1501
$8.8465
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
617-463-9385
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Vergleichen Sie APRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
3.05 | 16.58M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World
Aprea Therapeutics, Inc. Announces Twice Daily Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potential Optimize Clinical Outcomes and Strengthen Clinical Path Forward - Marketscreener.com
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MyChesCo
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward - The Manila Times
Aprea Therapeutics Advances Novel Cancer Drug Trial with Breakthrough Dosing Strategy - StockTitan
Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MSN
HC Wainwright Has Bullish Outlook for APRE FY2024 Earnings - Defense World
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher - MSN
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Aprea Therapeutics (NASDAQ: APRE) Announces Financial Results and Corporate Updates - Defense World
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Health Catalyst signs definitive agreement to acquire Intraprise Health - MSN
Aprea Therapeutics Inc (APRE) Quarterly 10-Q Report - Quartz
Aprea Therapeutics Inc (APRE) Q3 2024 Earnings: Revenue Hits $0. - GuruFocus.com
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo
Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN
DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR
Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews
Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World
Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa
Aprea therapeutics director sells shares worth $29,583 - Investing.com India
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com
Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK
Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance
Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha
Aprea reports safe trial results for new cancer drug - Investing.com
Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News
Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St
Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock By Investing.com - Investing.com South Africa
Aprea therapeutics CFO John Hamill acquires shares worth $123 - Investing.com
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock - Investing.com India
Aprea Therapeutics director Duey Marc buys $490 in stock - Investing.com
Aprea therapeutics CFO John Hamill acquires shares worth $123 By Investing.com - Investing.com South Africa
Aprea Therapeutics director Duey Marc buys $490 in stock By Investing.com - Investing.com South Africa
Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates - MSN
Aprea therapeutics director Bernd Seizinger buys $26,800 in stock By Investing.com - Investing.com Australia
Aprea Therapeutics president Gilad Oren buys $2,971 in stock - Investing.com India
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MyChesCo
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):